Literature DB >> 9469582

A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor.

C L Bisgaier1, A D Essenburg, B C Barnett, B J Auerbach, S Haubenwallner, T Leff, A D White, P Creger, M E Pape, T J Rea, R S Newton.   

Abstract

In the current studies we describe the effects of PD 72953 and related compounds on lipoprotein levels in chow-fed male rats. After 2 weeks, 10 mg/kg of PD 72953 daily was as effective as 100 mg/kg gemfibrozil for elevating HDL-cholesterol. At 100 mg/kg, PD 72953 further elevated HDL-cholesterol to 232% of control levels, and was associated with increased HDL size and plasma apoE (169% of control), despite no change in hepatic apoE mRNA. ApoA-I rose transiently (at 1 week), but by 2 weeks only apoE remained elevated. PD 72953 dose-dependently reduced plasma apoB, VLDL-cholesterol, LDL-cholesterol, and triglyceride. Hepatic apoC-III mRNA reduction parallelled triglyceride lowering. After 1 week, 30 and 100 mg/kg per day PD 72953 reduced plasma apo-CIII levels by 30 and 34%, and triglycerides by 60 and 83%, respectively. PD 72953 treatment had no effect on triglyceride production rates; however, 125I-labeled VLDL apoB disappearance was enhanced. We compared PD 72953 to a structurally similar diacid, PD 69405, that also reduced VLDL and LDL, but had no effect on HDL elevation. Compared to PD 72953, PD 69405 further accelerated 125I-labeled VLDL apoB disappearance, decreased triglyceride production, and elevated the ratio of post-heparin hepatic to lipoprotein lipase activity. Whole animal studies, transient transfection studies in HepG2 cells, and chimeric receptor studies in kidney 293 cells suggest that PD 72953 is a ligand for the peroxisomal proliferation activated receptor alpha (PPARalpha), and PPARgamma. Overall, PD 72953 may act through a peroxisomal proliferation activated receptor and result in plasma triglycerides and apoB-containing lipoprotein reduction, while also raising HDL cholesterol. Reduced apoC-III may allow triglyceride-rich remnants to more efficiently bind and present substrate to peripheral tissue lipoprotein lipase, and therefore allow enhanced shedding of remnant phospholipid surface for HDL production.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9469582

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  12 in total

1.  Antidyslipidemic and antioxidant effects of novel Lupeol-derived chalcones.

Authors:  Shishir Srivastava; Ravi Sonkar; Sunil Kumar Mishra; Avinash Tiwari; Vishal M Balaramnavar; Vishal Balramnavar; Snober Mir; Gitika Bhatia; Anil K Saxena; Vijai Lakshmi
Journal:  Lipids       Date:  2013-08-14       Impact factor: 1.880

Review 2.  Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future.

Authors:  Daniel H van Raalte; Min Li; P Haydn Pritchard; Kishor M Wasan
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

Review 3.  Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future.

Authors:  Evan A Stein; Frederick J Raal
Journal:  Curr Cardiol Rep       Date:  2015-11       Impact factor: 2.931

4.  Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice.

Authors:  Rai Ajit K Srivastava; Ravi Jahagirdar; Salman Azhar; Somesh Sharma; Charles L Bisgaier
Journal:  Mol Cell Biochem       Date:  2006-02-14       Impact factor: 3.396

5.  AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism.

Authors:  Stephen L Pinkosky; Sergey Filippov; Rai Ajit K Srivastava; Jeffrey C Hanselman; Cheryl D Bradshaw; Timothy R Hurley; Clay T Cramer; Mark A Spahr; Ashley F Brant; Jacob L Houghton; Chris Baker; Mark Naples; Khosrow Adeli; Roger S Newton
Journal:  J Lipid Res       Date:  2012-11-01       Impact factor: 5.922

Review 6.  Update on Therapeutic Options in Lipodystrophy.

Authors:  Baris Akinci; Rasimcan Meral; Elif Arioglu Oral
Journal:  Curr Diab Rep       Date:  2018-10-29       Impact factor: 4.810

7.  Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH.

Authors:  Daniela Carmen Oniciu; Taishi Hashiguchi; Yuichiro Shibazaki; Charles L Bisgaier
Journal:  PLoS One       Date:  2018-05-30       Impact factor: 3.240

8.  An AMPK activator as a therapeutic option for congenital nephrogenic diabetes insipidus.

Authors:  Janet D Klein; Ish Khanna; Ram Pillarisetti; Rachael A Hagan; Lauren M LaRocque; Eva L Rodriguez; Jeff M Sands
Journal:  JCI Insight       Date:  2021-04-22

Review 9.  Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis.

Authors:  Virender Kumar; Xiaofei Xin; Jingyi Ma; Chalet Tan; Natalia Osna; Ram I Mahato
Journal:  Adv Drug Deliv Rev       Date:  2021-07-24       Impact factor: 17.873

10.  Gemcabene, a First-in-Class Hypolipidemic Small Molecule in Clinical Development, Attenuates Osteoarthritis and Pain in Animal Models of Arthritis and Pain.

Authors:  Rai A K Srivastava; Joseph A Cornicelli; Bruce Markham; Charles L Bisgaier
Journal:  Front Pharmacol       Date:  2018-05-11       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.